PE-22-28 8mg

Description:

PE-22-28 is a synthetic variation of the naturally existing peptide known as spadin, which has an affinity for binding to TREK-1. TREK-1 is present in specific brain regions that regulate mood, memory, and learning. Researchers are investigating PE-22-28 for its potential in various areas, including antidepressant effects, enhancement of learning, aiding in stroke recovery, and addressing neurodegenerative conditions like Alzheimer’s disease.

PE-22-28 Research:

Research on TREK-1 has focused on understanding its physiological functions and potential implications in various diseases. Here are some key areas of investigation related to TREK-1:

• Physiological Functions: TREK-1 channels are widely expressed throughout the body, including the brain, heart, lungs, and kidneys. Studies have shown that TREK-1 channels contribute to the regulation of resting membrane potential and control the excitability of neurons and other cell types. They are involved in the modulation of neuronal firing, pain perception, cardiovascular function, and pulmonary regulation.
• Neuroprotection: TREK-1 channels have been implicated in neuroprotection, particularly in ischemic conditions. Activation of TREK-1 channels has shown to have a neuroprotective effect in animal models of stroke, reducing brain damage and improving neurological outcomes. Researchers are investigating the underlying mechanisms and exploring the potential therapeutic applications of targeting TREK-1 channels in ischemic stroke and other neurodegenerative disorders.
• Mood and Anxiety Disorders: There is growing evidence suggesting a role for TREK-1 channels in mood regulation and anxiety disorders. Animal studies have demonstrated that TREK-1 knockout mice exhibit anxiolytic-like behavior, indicating that inhibiting TREK-1 activity may have therapeutic potential for anxiety disorders. Additionally, TREK-1 channels have been implicated in the mechanisms of action of certain antidepressant drugs. Further research is needed to fully understand the involvement of TREK-1 in these psychiatric conditions.
• Pain Perception: TREK-1 channels are expressed in sensory neurons and have been implicated in pain perception and modulation. Animal studies have shown that TREK-1 knockout mice display altered responses to thermal and mechanical pain stimuli. Modulating TREK-1 channel activity may hold promise for the development of novel analgesic strategies.
• Drug Discovery: Given the involvement of TREK-1 channels in various physiological and pathological processes, there is increasing interest in developing selective modulators of TREK-1 activity for therapeutic purposes. Researchers are exploring small molecules, peptides, and other compounds that can selectively activate or inhibit TREK-1 channels, with the goal of developing novel treatments for neurological disorders, cardiovascular diseases, and other conditions.